PKIG: A Potential Drug Target and Biomarker (G11142)

Target Name: PKIG

NCBI ID: G11142

PKIG

PKIG: A Potential Drug Target and Biomarker

PKIG, short for Pyruvate Kinase GTPase, is a protein that plays a crucial role in the metabolism of pyruvate, a critical intermediate step in the citric acid cycle (also known as the Krebs cycle or TCA cycle). The pyruvate cycle is a central metabolic pathway that generates energy and amino acids from simple sugars, including glucose. PKIG is the enzyme that catalyzes the final step of the pyruvate cycle, converting pyruvate to acetyl-CoA, which is then used to produce carbon dioxide and water.

PKIG is a 26-kDa protein that is expressed in most tissues and is involved in the metabolism of both low- and high-energy aerobic metabolism. It is a key regulator of the pyruvate cycle and is involved in the final step of its catalytic cycle, the conversion of pyruvate to acetyl-CoA. PKIG has been shown to play a crucial role in the regulation of cellular metabolism and has been implicated in a wide range of physiological processes, including the development and progression of cancer, obesity, and neurodegenerative diseases.

Despite its importance in cellular metabolism, PKIG has not yet been identified as a drug target or biomarker. This is because its function and the mechanisms that regulate its activity are not well understood. However, recent studies have identified potential drug targets and biomarkers that may interact with PKIG.

One potential drug target for PKIG is the inhibition of the activity of PKIG has been shown to have therapeutic effects in a wide range of diseases, including cancer, neurodegenerative diseases, and obesity. For example, studies have shown that inhibiting the activity of PKIG has been shown to inhibit the growth of cancer cells and to reduce the progression of neurodegenerative diseases. Additionally, inhibiting PKIG has been shown to reduce the levels of body fat and to improve insulin sensitivity, which can be useful for the treatment of obesity and type 2 diabetes.

Another potential biomarker for PKIG is the measurement of PKIG activity in tissues or fluids. This can be done by using techniques such as Western blotting, which involves the use of antibodies to detect specific protein bands in tissues or fluids. By measuring the levels of PKIG activity in tissues or fluids, researchers can gain insights into the regulation of cellular metabolism and the potential utility of PKIG as a drug target or biomarker.

In conclusion, PKIG is a protein that plays a crucial role in the regulation of cellular metabolism and has been implicated in a wide range of physiological processes, including the development and progression of cancer, obesity, and neurodegenerative diseases. Despite its importance, PKIG has not yet been identified as a drug target or biomarker. However, recent studies have identified potential drug targets and biomarkers that may interact with PKIG, and further research is needed to fully understand its function and potential utility as a therapeutic agent.

Protein Name: CAMP-dependent Protein Kinase Inhibitor Gamma

Functions: Extremely potent competitive inhibitor of cAMP-dependent protein kinase activity, this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulatory chains

The "PKIG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PKIG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets